What is William Blair's Estimate for Zoetis Q2 Earnings?

Zoetis Inc. (NYSE:ZTS - Free Report) - William Blair raised their Q2 2025 earnings per share estimates for shares of Zoetis in a research note issued to investors on Tuesday, May 6th. William Blair analyst B. Vazquez now expects that the company will post earnings of $1.62 per share for the quarter, up from their previous forecast of $1.59. The consensus estimate for Zoetis' current full-year earnings is $6.07 per share. William Blair also issued estimates for Zoetis' Q3 2025 earnings at $1.65 EPS, Q4 2025 earnings at $1.50 EPS, FY2025 earnings at $6.26 EPS, Q1 2026 earnings at $1.59 EPS, Q2 2026 earnings at $1.78 EPS, Q3 2026 earnings at $1.79 EPS, Q4 2026 earnings at $1.63 EPS and FY2026 earnings at $6.80 EPS.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. During the same period in the prior year, the company earned $1.38 EPS. Zoetis's revenue for the quarter was up 1.4% on a year-over-year basis.

Several other brokerages have also recently weighed in on ZTS. Piper Sandler increased their price target on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday. Barclays raised their target price on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. Morgan Stanley decreased their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. UBS Group decreased their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Finally, StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. One analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of "Buy" and an average price target of $212.75.

Zoetis Trading Up 1.5%

Shares of ZTS stock traded up $2.41 on Friday, hitting $161.68. The company had a trading volume of 3,453,718 shares, compared to its average volume of 2,496,816. The firm has a market cap of $72.14 billion, a P/E ratio of 29.56, a P/E/G ratio of 2.78 and a beta of 0.94. The stock's 50-day moving average is $157.27 and its two-hundred day moving average is $165.95. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis has a twelve month low of $139.70 and a twelve month high of $200.33.

Institutional Trading of Zoetis

Several institutional investors have recently added to or reduced their stakes in ZTS. Principal Financial Group Inc. raised its holdings in Zoetis by 17.3% during the third quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company's stock valued at $464,497,000 after acquiring an additional 351,372 shares during the period. JPMorgan Chase & Co. grew its position in Zoetis by 10.6% in the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company's stock worth $569,834,000 after acquiring an additional 279,092 shares in the last quarter. Douglas Lane & Associates LLC grew its position in Zoetis by 1,076.1% in the fourth quarter. Douglas Lane & Associates LLC now owns 97,395 shares of the company's stock worth $15,869,000 after acquiring an additional 89,114 shares in the last quarter. Baker Tilly Wealth Management LLC boosted its position in shares of Zoetis by 20.6% during the fourth quarter. Baker Tilly Wealth Management LLC now owns 2,080 shares of the company's stock valued at $339,000 after buying an additional 356 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its position in shares of Zoetis by 64.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 409,703 shares of the company's stock valued at $66,753,000 after buying an additional 160,826 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71% decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,862 shares of company stock valued at $312,254 in the last 90 days. Insiders own 0.18% of the company's stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.